Literature DB >> 23546728

Antithrombin.

Mirta Hepner1, Vasiliki Karlaftis.   

Abstract

Antithrombin (AT) is a heparin cofactor and a member of the serine protease inhibitor family (serpin). The mature AT molecule is composed of 432 amino acids and it is produced mainly in the liver. Initially, several different AT activities in plasma were reported, leading to the classification of antithrombin in a range from I to IV. It was subsequently shown that these various antithrombin activities were the function of one molecule, antithrombin III, whose name was reduced to antithrombin at the meeting of the International Society in Thrombosis and Haemostasis in 1993. AT is an important protease inhibitor of thrombin and factor Xa. However, AT is also able to inhibit factors IXa, XIa, XIIab, kallikrein, and plasmin. Given that AT is one of the major naturally occurring inhibitors of coagulation, acquired or hereditary deficiencies of this protein result in excessive thrombin generation. As a vast array of mutations are responsible for hereditary AT deficiencies, screening for their presence by DNA testing would require sequencing each entire gene involving numerous exons. Moreover, the knowledge of the gene mutation does not offer any benefit in the treatment of affected families, so the routine molecular characterization is not indicative. These defects are detected by functional or immunological assays. AT amidolytic assays are recommended for initial testing for AT deficiency. There is no need to routinely perform AT immunological assays. However, they are useful in order to distinguish type I from type II hereditary AT deficiency.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23546728     DOI: 10.1007/978-1-62703-339-8_28

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  12 in total

Review 1.  A Molecular Revolution in the Treatment of Hemophilia.

Authors:  John S S Butterfield; Kerry M Hege; Roland W Herzog; Radoslaw Kaczmarek
Journal:  Mol Ther       Date:  2019-11-13       Impact factor: 11.454

2.  Combining Heparin and a FX/Xa Aptamer to Reduce Thrombin Generation in Cardiopulmonary Bypass and COVID-19.

Authors:  Charlene V Chabata; James W Frederiksen; Lyra B Olson; Ibtehaj A Naqvi; Sharon E Hall; Ruwan Gunaratne; Bryan D Kraft; Loretta G Que; Lingye Chen; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2022-01-12       Impact factor: 4.244

Review 3.  Digestive Inflammation: Role of Proteolytic Dysregulation.

Authors:  Vincent Mariaule; Aicha Kriaa; Souha Soussou; Soufien Rhimi; Houda Boudaya; Juan Hernandez; Emmanuelle Maguin; Adam Lesner; Moez Rhimi
Journal:  Int J Mol Sci       Date:  2021-03-10       Impact factor: 5.923

Review 4.  Thrombin activation and liver inflammation in advanced hepatitis C virus infection.

Authors:  Emilio González-Reimers; Geraldine Quintero-Platt; Candelaria Martín-González; Onán Pérez-Hernández; Lucía Romero-Acevedo; Francisco Santolaria-Fernández
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

Review 5.  Anticoagulation in ECMO patients: an overview.

Authors:  Gaurav Kumar; Ashish Maskey
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-03-23

6.  Clinical Significance of Serum Antithrombin III Activity After Hepatectomy for Hepatocellular Carcinoma.

Authors:  Naruo Tokuyasu; Masataka Amisaki; Takehiko Hanaki; Yuki Murakami; Masaki Morimoto; Ei Uchinaka; Takuki Yagyu; Keisuke Goto; Tomoyuki Matsunaga; Manabu Yamamoto; Shuichi Takano; Teruhisa Sakamoto; Soichiro Honjo; Toshimichi Hasegawa; Yoshiyuki Fujiwara
Journal:  Yonago Acta Med       Date:  2021-04-15       Impact factor: 1.641

Review 7.  Update of the human and mouse SERPIN gene superfamily.

Authors:  Claire Heit; Brian C Jackson; Monica McAndrews; Mathew W Wright; David C Thompson; Gary A Silverman; Daniel W Nebert; Vasilis Vasiliou
Journal:  Hum Genomics       Date:  2013-10-30       Impact factor: 4.639

8.  Heparin Saline Versus Normal Saline for Flushing and Locking Peripheral Venous Catheters in Decompensated Liver Cirrhosis Patients: A Randomized Controlled Trial.

Authors:  Rui Wang; Ming-Guang Zhang; Ou Luo; Liu He; Jia-Xin Li; Yun-Jing Tang; Yan-Li Luo; Min Zhou; Li Tang; Zong-Xia Zhang; Hao Wu; Xin-Zu Chen
Journal:  Medicine (Baltimore)       Date:  2015-08       Impact factor: 1.889

Review 9.  Clinical Scenarios for Discordant Anti-Xa.

Authors:  Jesus Vera-Aguilera; Hindi Yousef; Diego Beltran-Melgarejo; Teng Hugh Teng; Ramos Jan; Mary Mok; Carlos Vera-Aguilera; Eduardo Moreno-Aguilera
Journal:  Adv Hematol       Date:  2016-05-12

10.  Serpin functions in host-pathogen interactions.

Authors:  Jialing Bao; Guoqing Pan; Mortimer Poncz; Junhong Wei; Maoshuang Ran; Zeyang Zhou
Journal:  PeerJ       Date:  2018-04-05       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.